Expert disagreements, alternative perspectives, and minority opinions.
“Treating obesity and type 2 diabetes primarily as a 'peptide deficiency' medicalises what is actually a social and environmental issue. Widespread adoption of expensive long-term pharmacology like semaglutide or tirzepatide may distract from the structural changes — regulating ultra-processed foods, rebuilding food environments — that would address the upstream cause.”
Detail
A peptide protocol alone cannot fix a broken food environment. Read this critique as a reminder that the intervention lives on top of an environmental base, not as a replacement for changes to that base. At the individual level, the drugs still work; at the population level, the diagnosis may be incomplete.
“The 'epigenetic switch' mechanism attributed to tetrapeptides like Pankragen lacks the large-scale, double-blind, multi-centre Phase III trials required for validation in the US or EU. The restorative claims for pancreatic function may be overstated due to reliance on localised or off-label clinical settings rather than pre-registered international RCTs.”
Detail
Treat Pankragen as Tier-3 evidence: substantial Russian clinical record, thin Western validation, FDA-treats-with-skepticism status. Do not frame it as a replacement for Tier-1 incretin therapy. Use is a judgement call about which evidence standard applies, not a settled recommendation.
“Maintaining supraphysiological GLP-1 or GIP signalling over years may lead to receptor down-regulation and permanent shifts in the body's satiety and energy-expenditure set points. Once the pharmacological drive is removed, the body may be less capable of maintaining homeostasis than before treatment — a form of drug-induced dependency the original trials were never designed to detect.”
Detail
This is the unresolved long-term risk. Post-discontinuation weight regain is well-documented for GLP-1 therapy; whether that reflects return-to-baseline biology or genuine set-point damage is not settled. Plan for long-term therapy rather than short courses, or build in supervised discontinuation protocols with adequate follow-up.
“GLP-1 agonists interact with the brain's dopamine reward pathways. Some patients report loss of interest not just in food, but in other rewarding activities — social, creative, sexual. The clinical framing of 'satiety' and 'appetite suppression' does not adequately capture this broader affective flattening.”
Detail
Not universal, usually reversible on discontinuation, but genuinely under-characterised. Worth flagging to patients prospectively. If quality-of-life symptoms appear during therapy, raise with the prescriber rather than normalising them. This is an under-discussed dimension of what these drugs do.
“Ancestral stressors — exercise, fasting, cold exposure, heat — stimulate endogenous incretin and mitochondrial-derived peptide release. The naturalist position is that these should be exhausted first, since they engage the body's native feedback loops rather than bypassing them with synthetic analogues. Synthetic signalling is a blunt instrument compared to the body's own regulated release.”
Detail
For mild metabolic dysregulation, lifestyle intervention first is often the correct starting point — and would be treated as first-line by most evidence-based clinicians too. The position becomes contrarian only when applied to established type-2 diabetes, where Tier-1 pharmacology has outcome data that lifestyle alone does not reach. The truth sits in between: lifestyle is non-negotiable as a foundation; pharmacology is how you cover the gap lifestyle cannot close.